Condition: Spinal Cord Injury · Traumatic Spinal Cord Injury · Paraplegia and Tetraplegia · Sponsor: Northwell Health
The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.
This description comes directly from the study's public registry record.
Ona Bloom, PhD · 516-562-1309 · obloom@northwell.edu
Always discuss trial participation with your own doctor first.
| Kessler Institute for Rehabilitation | West Orange, New Jersey, United States | Not Yet Recruiting |
| Northwell Health | Manhasset, New York, United States | Recruiting |
| James J. Peters VA Medical Center | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07625332